Al Reba is driven by a passion for bold science and groundbreaking innovation that transforms lives. With more than 25 years at Bristol Myers Squibb (BMS), he has dedicated his career to delivering hope and life-changing medicines to patients around the world.

Since February 2025, Reba has served as SVP of Immunology & Cardiovascular Commercialization. In this role, he oversees US commercial and global commercial strategy for key marketed products, including an oral anticoagulant that has benefited more than 55 million patients worldwide, a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy, and therapies for rheumatoid arthritis, psoriasis, and psoriatic arthritis. He also spearheads the commercialization of a partnered investigational asset being studied in atrial fibrillation and secondary stroke prevention, and investigational assets across various immune-mediated disorders including pulmonary fibrosis and lupus disease.

Since joining BMS in 1999, Reba has taken on roles of increasing responsibility across diverse therapeutic areas, including cardiovascular, neuroscience, metabolics, and oncology. Highlights of his career include serving as the US cardiovascular launch lead, general manager of BMS Canada, and most recently, SVP of US Cardiovascular and Established Brands. Prior to BMS, he worked with Andersen Consulting as an information technology and strategy consultant.

Reba earned his BS in Industrial Engineering and Operations Research from Cornell University. He holds an MBA from the University of Michigan Business School. He lives in New Jersey with his wife and their three children.